The FDA has officially approved Awiqli® (insulin icodec-abae) — the first once-weekly basal insulin for adults with Type 2 Diabetes! 🎉
🚨 BREAKTHROUGH IN DIABETES CARE! 🚨
Instead of daily basal insulin injections, patients may now need just ONE injection per week, potentially transforming diabetes management for millions of people.
Supported by large Phase 3 clinical trials involving thousands of participants, Awiqli demonstrated strong blood sugar control and represents one of the biggest insulin innovations in more than 20 years.
Doctors, researchers, and patients around the world are calling this a major step forward in diabetes treatment and medication adherence.
Could once-weekly insulin become the future of diabetes care? 👇
